ReviewCell death discovery2025
Ferroptosis in diabetes mellitus and its complications: overview of clinical and preclinical research.
Review in Cell death discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Icariin-loaded liposomal nanoparticles alleviate streptozotocin-induced diabetic hepatopathy associated with modulation of ferroptosis-related and inflammatory signaling.BMC pharmacology & toxicology · 2026Article
- CNP-miR146a Promotes NRF2-Related Ferroptosis-Protective Myeloid Programs and Immune-Vascular Regeneration in Diabetic Wounds.Pharmaceutics · 2026Article
- Targeting Ferroptosis, Pyroptosis, and NRF2 Signaling with Dietary Polyphenols in Diabetic Microvascular Complications: An Integrative Review.Nutrients · 2026Review
- IDH2 deficiency enhances ferroptosis-induced vascular inflammation and remodeling in diabetes.Scientific reports · 2026Article
- The Role of Ferroptosis in Diabetes Pathogenesis: Therapeutic Implications of Hydrogen Sulfide and Its Reactive Metabolites.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus, a metabolic disorder of rising global incidence, imposes substantial health burdens through its systemic complications. Although the treatment strategies based on pathological changes and molecular mechanisms are constantly upgrading, the therapeutic effects, especially for complications, are not satisfactory. Emerging evidence highlights ferroptosis-an iron-dependent cell death pathway-as a critical regulator in diabetic pathophysiology. This review synthesizes clinical data, genetic studies, and therapeutic interventions across experimental models to establish ferroptosis's multifaceted involvement in diabetes progression. Multiorgan analyses (pancreatic islets, heart, kidney, liver, brain, etc.) reveal ferroptosis-mediated pathways connecting localized tissue damage to systemic diabetic pathogenesis. Particularly, ferroptosis intersects with characteristic diabetic mechanisms, including oxidative stress, lipid peroxidation, and mitochondrial dysfunction. Our integrated assessment positions ferroptosis as a converging pathological mechanism in diabetes, proposing its molecular mediators as promising targets for innovative combination therapies. This mechanistic understanding could enable novel approaches for mitigating both metabolic dysregulation and end-organ damage in diabetes management.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.